Articles By Rob Wright, Chief Editor 2011-2021

-
Nothing Ventured, Nothing Learned9/3/2018
This month’s issue, like many before, features a variety of executives who have demonstrated a willingness to take significant risks.
-
One-On-One With Tony Coles, CEO Of Yumanity Therapeutics9/3/2018
Six months after Amgen acquired Onyx Pharmaceuticals, Tony Coles, M.D. was pondering his next move. The former Onyx CEO wasn’t planning to lead another pharma company so soon … but then he got a phone call.
-
What Mylan Could Learn About Accountability8/31/2018
Mylan’s inability to adequately supply its EpiPen during the 2018 back-to-school time is the latest example of corporate leadership lacking accountability.
-
Are Genetically Modified Organisms (GMO) A Blessing Or A Curse?8/27/2018
A question about GMOs submitted to our editorial board leads us to look more closely into this issue and how it affects the pharma industry.
-
Why A Biopharma Executive Founded A Game-Changing Conference8/20/2018
Amir Kalali, M.D., former global head of Quintiles (now IQVIA) neuroscience center of excellence, provides insight on why he decided to found an educational conference, The CNS Summit, while still working as a biopharmaceutical industry executive.
-
Is It Possible For A Biopharmaceutical Executive To Transcend Their Industry?8/9/2018
What current biopharma leaders have the potential to “transcend” beyond this industry? Chief Editor Rob Wright gives his top three choices.
-
Readying Sanofi For The Era Of Digital Health8/2/2018
Ameet Nathwani, M.D., EVP of medical function at Sanofi, gives the inside scoop on what’s required when it comes to preparing a Big Pharma to be digital-health ready.
-
How To Broker Strategic Alliances Between International Biopharma Stakeholders8/2/2018
A summary from the BIO conference panel “Don’t Be Foreign To Foreign Affairs — How To Broker Biopharma Strategic Alliances And Partnerships Between International Stakeholders”
-
Is Biopharma Ready For AI?8/2/2018
Is the pharma industry ready to move beyond the buzz regarding terms like terms like AI, digital health, and machine learning (ML)?